Drug Profile
Research programme: tuberculosis therapeutics - Mycosynthetix
Latest Information Update: 28 Jul 2020
Price :
$50
*
At a glance
- Originator Mycosynthetix Inc
- Developer Mycosynthetix Inc; University of Illinois at Chicago
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Tuberculosis
Most Recent Events
- 28 Jul 2020 No recent reports of development identified for research development in Tuberculosis in USA
- 30 Jun 2016 Early research in Tuberculosis in USA (unspecified route)